Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy

Vaccine

Volumn 25, Issue 5, 2007, Pages 957-964

  Rossi, Renato E ^a   Monasterolo, Giorgio ^b   Coco, Giuseppe ^b   Silvestro, Luisa ^b   Operti, Daniela ^b  

^a National Health Service   (Italy)

^b Laboratorio Analisi Chimico Cliniche e Microbiologia   (Italy)

Author keywords

IgG4; Phleum pratense; Recombinant allergens; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; ALUTARD; ALUTARD SQ; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN G4; POLLEN ANTIGEN; SLIT ONE; STALORAL 300; TIMOTHY GRASS POLLEN EXTRACT VACCINE; VACCINE;

ADULT; ALLERGY; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MALE; PATIENT; PHLEUM PRATENSE; PRIORITY JOURNAL; SLIT LAMP;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; CHILD; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHIL CATIONIC PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN G; MALE; POACEAE; POLLEN;

EID: 33845301687     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.040     Document Type: Article

References (38)

1. Clavel R., Bousquet J., and André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53 (1998) 493-498
2. Feliziani V., Lattuada G., Parmiani S., and Dall'Aglio P.P. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 23 (1995) 224-230
3. Quirino T., Iemoli E., Siciliani E., Parmiani S., and Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 26 (1996) 1253-1261
4. Vourdas D., Syrigou E., Potamianou P., Carat F., Batard T., André C., et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53 (1998) 662-672
5. Bousquet J., Scheinmann P., Guinnepain M.T., Perrin-Fayolle M., Sauvaget J., Tonnel A.B., et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebocontrolled study. Allergy 54 (1999) 249-260
6. Canonica G.W., and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 (2003) 437-449
7. Passalacqua G., Albano M., Fregonese L., Riccio A., Pronzato C., Mela G.S., et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351 (1998) 629-632
8. Marcucci F., Sensi L., Di Cara G., Salvatori S., Bernini M., Pecora, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 16 (2005) 519-526
9. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 (1998) 558-562
10. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33 (2003) 206-210
11. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E., et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004) 851-857
12. Bufe A., Ziegler-Kirbach E., Stoeckmann E., Heidemann P., Gehlhar K., Holland-Letz T., et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 59 (2004) 498-504
13. Passalacqua G., Guerra L., Pasquali M., Lombardi C., and Canonica G.W. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 93 (2004) 3-12
14. Smith H., White P., Annila I., Poole J., André C., and Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 114 (2004) 831-837
15. Bahceciler N.N., Arikan C., Taylor A., Akdis M., Blaser K., Barman I.B., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 136 (2005) 287-294
16. Khinchi M.S., Poulsen L.K., Carat F., André C., Hansen A.B., and Malling H.-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
17. Marogna M., Spadolini I., Massolo A., Canonica G.W., and Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 115 (2005) 1184-1188
18. Gidaro G.B., Marcucci F., Sensi L., Incorvaia C., Frati F., and Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 35 (2005) 565-571
19. Rossi R.E., and Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific antibodies induced by subcutaneous timothy pollen extract immunotherapy in allergic patients. Int Arch Allergy 135 (2004) 44-53
20. Rossi R.E., and Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 min) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 18 (2005) 277-285
21. Rossi R.E., Monasterolo G., Coco G., and Operti D. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol 138 (2005) 105-110
22. Garcia B.E., Sanz M.L., Gato J.J., Fernandez J., and Oehling A. IgG4 blocking effect on the release of antigen-specific histamine. J Invest Allergol Clin Immunol 3 (1993) 26-33
23. van Neerven R.J.J., Wikborg T., Lund G., Jacobsen B., Brinch-Nielsen A., Arnved J., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163 (1999) 2944-2952
24. Till S.J., Francis J.N., Nouri-Aria K., and Durham S.R. Mechanisms of immunotherapy. J Allergy Clin Immunol 113 (2004) 1025-1034
25. Visco V., Dolecek C., Denepoux S., LeMao J., Guret C., Rousset F., et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 157 (1996) 956-962
26. Flicker S., and Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 132 (2003) 13-24
27. Akdis M., Schmidt-Weber C., Jutel M., Akdis C.A., and Blaser K. Mechanism of allergen immunotherapy. Clin Exp All Rev 4 (2004) 56-60
28. Rolinck-Werninghaus C., Kopp M., Liebke C., Lange J., Wahn U., and Niggerman B. Lack of detectable alterations in immune response during sublingual immunotherapy in children with seasonal allergic rhinoconjuctivitis to grass pollen. Int Arch Allergy Immunol 136 (2005) 134-141
29. Dehlink E., Eiwegger T., Gerstmayr M., Kampl E., Bohole B., Chen K.-W., et al. Absence of systemic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 36 (2006) 32-39
30. De Weerd N., Bhalla P.L., and Singh M.B. Oral immunization with a recombinant major grass pollen allergen induces blocking antibodies in mice. Int Arch Allergy Immunol 130 (2003) 119-124
31. Klein F., Skavaril F., Vermeeren R., Vlug A., and Duimel W.J. The quantification of human IgG subclasses in reference preparations. Clin Chim Acta 150 (1985) 119-127
32. Lima M.T., Wilson D., Pitkin L., Roberts A., Nouri-Aria K., Jacobson, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 32 (2002) 507-514
33. Kolbe L., Heusser C.H., and Kölsch E. Isotype-associated recognition of allergen epitopes and its modulation by antigen dose. Immunology 84 (1995) 285-289
34. Kihlström A., Hedlin G., Pershagen G., Troye-Blomberg M., Härfast B., and Lilja G. Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic in the child. Clin Exp Allergy 35 (2005) 1542-1549
35. Wachholz P.A., Kristensen Soni N., Till S.J., and Durham S.R. Inhibition of allergen-IgE binding to B cells by IgG antibodies following grass pollen immunotherapy. J Allergy Clin Immunol 112 (2003) 915-922
36. Fanta C., Bohle B., Hirt W., Siemann U., Horak F., Kraft D., et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 120 (1999) 218-224
37. Pradalier A., Basset D., Claudel A., Couturier P., Wessel F., Galvain S., et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54 (1999) 819-828
38. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809